1984 Volume 32 Issue Supplement4 Pages 188-191
Sulbactam, a new β-lactamase inhibitor, was an irreversible inhibitor of several bacterial penicillinase and cephalosporinase. Clinical effects on combination of sulbactam and cefoperazone (SBT/CPZ) were investigated and following results were obtained.
SBT/CPZ was administrated by intravenous drip infusion to 6 patients of RTI, 9 patients of UTI, 1 patient of BTI. And 2 grams of SBT/CPZ was administrated twice a day for 4 to 21 days. Clinical efficacy rate was 63% in 16 patients. As side effects, diarrhea was observed in 1 patient, and neutropenia was observed in other 1 patient.
